Nomad Internet Launches “NomadCares” $75 Redemption Program Recce Pharmaceuticals Announces RECCE® Trademark Registered in Vietnam, Strengthening Global IP Portfolio
SYDNEY, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q)…
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Vietnam, Strengthening Global IP Portfolio
SYDNEY, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q)…
Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic…
Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic…
electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023
CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023
CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the…
BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the…
Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023
• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza…
Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023
• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza…
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…
Avalyn Pharma’s Inhaled Pulmonary Fibrosis Programs to be Highlighted at Upcoming ERS International Congress
Interstitial Lung Disease Experts Present Forced Vital Capacity Results from ATLAS Study Seattle, Sept. 07,…
Avalyn Pharma’s Inhaled Pulmonary Fibrosis Programs to be Highlighted at Upcoming ERS International Congress
Interstitial Lung Disease Experts Present Forced Vital Capacity Results from ATLAS Study Seattle, Sept. 07,…
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot…
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot…
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
First patient has been enrolled in the Dose Confirmation stage (n=18) of the Phase 2…
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
First patient has been enrolled in the Dose Confirmation stage (n=18) of the Phase 2…